Biodesix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 02:36 am IST
Share
Biodesix, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 13.49 million compared to USD 11.11 million a year ago. Net loss was USD 10.95 million compared to USD 13.7 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.34 a year ago.
For the nine months, sales was USD 34.42 million compared to USD 28.61 million a year ago. Net loss was USD 43.01 million compared to USD 45.11 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 1.22 a year ago.
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.